ReNeuron Group PLC
LSE:RENE
Intrinsic Value
ReNeuron Group Plc engages in the development of novel cell based therapies that target significant areas of unmet medical need. [ Read More ]
The intrinsic value of one RENE stock under the Base Case scenario is 194.8 GBX. Compared to the current market price of 3.375 GBX, ReNeuron Group PLC is Undervalued by 98%.
Fundamental Analysis
Balance Sheet Decomposition
ReNeuron Group PLC
| Current Assets | 5.8m |
| Cash & Short-Term Investments | 5.1m |
| Receivables | 670k |
| Non-Current Assets | 670k |
| PP&E | 490k |
| Intangibles | 190k |
| Other Non-Current Assets | -10k |
| Current Liabilities | 3.8m |
| Accounts Payable | 3.7m |
| Other Current Liabilities | 150k |
| Non-Current Liabilities | 190k |
| Long-Term Debt | 190k |
Earnings Waterfall
ReNeuron Group PLC
|
Revenue
|
250k
GBP
|
|
Operating Expenses
|
-6.4m
GBP
|
|
Operating Income
|
-6.1m
GBP
|
|
Other Expenses
|
1.1m
GBP
|
|
Net Income
|
-5.1m
GBP
|
Free Cash Flow Analysis
ReNeuron Group PLC
RENE Profitability Score
Profitability Due Diligence
ReNeuron Group PLC's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Score
ReNeuron Group PLC's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
RENE Solvency Score
Solvency Due Diligence
ReNeuron Group PLC's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Score
ReNeuron Group PLC's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RENE Price Targets Summary
ReNeuron Group PLC
Shareholder Return
RENE Price
ReNeuron Group PLC
| Average Annual Return | -48.13% |
| Standard Deviation of Annual Returns | 31.94% |
| Max Drawdown | -99% |
| Market Capitalization | 1.9m GBX |
| Shares Outstanding | 57 173 800 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
ReNeuron Group Plc engages in the development of novel cell based therapies that target significant areas of unmet medical need. The company is headquartered in Bridgend, Glamorgan and currently employs 43 full-time employees. The company went IPO on 2005-08-12. The firm develops allogeneic stem cell technology platforms, stem cell derived exosomes and induced pluripotent stem cells. The firm's products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used for the treatment of retinitis pigmentosa (RP). The firm's exosomes nanomedicine platform focuses on generating early pre-clinical data in cancer. Its ReNcell Products include ReNcellVM and ReNcellCX cell lines. The company is engaged in Phase II clinical trial of CTX cells for stroke disability. The company is engaged in Phase I clinical trial of CTX cells for Critical Limb Ischaemia. The company is engaged in Phase I clinical trial of hRPC stem cell candidate.
You don't have any saved screeners yet
